This article was originally published in The Gray Sheet
Executive SummaryDistribution partner for Acculaser Pro iliotibial band syndrome treatment system is sought by the firm following recent 510(k) clearance, Photothera says. Priced at $6,995, the non-invasive device uses light energy emitted from a probe to accelerate healing of a knee injury common to runners. Expanded use of the technology for stroke patients is expected in the future; a related study will begin outside the U.S. later this year, according to the firm...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.